Allergan
Allergan slashes 1,500 jobs
July 22, 2014Research and Development, Sales and Marketing Allergan, Botox, Jobs, cuts, valiant
Allergan is to cut 1,500 jobs as part of a restructure which it believes will make pre-tax savings of around …
Valeant goes hostile over Allergan hunt
June 19, 2014Sales and Marketing Allergan, Botox, Valeant, hostile, takeover
Valeant Pharmaceuticals has turned hostile in its bid to acquire Botox maker Allergan by employing strong-arm tactics in an attempt …
Allergan rejects Valeant – again
June 11, 2014Research and Development, Sales and Marketing Allergan, Botox, Valeant, pershing, pharma
Allergan and Valeant Pharmaceuticals International are continuing their stately dance around one another – and in the latest move the …
Valeant ‘substantially undervalues’ Allergan
May 13, 2014Sales and Marketing Allergan, Botox, Pfizer, Valeant, buyout, merger
Allergan’s board has issued a defiant, unanimous rejection of the multi-billion dollar takeover offer made public by Valeant last month. In …
Valeant makes $45.7 billion Allergan offer
April 23, 2014Sales and Marketing Allergan, Botox, GSK, Novartis, Pfizer, Valeant, merger, pershing
In the latest proposal in a flurry of merger and acquisition activity in the pharma sector, Valeant Pharmaceuticals International wants …
Allergan reprimanded over Botox promotion
March 19, 2014Medical Communications, Sales and Marketing ABPI, Allergan, Botox, Galderma, PMCPA, vistabel
Allergan has been found guilty of breaching six clauses of the ABPI’s Code of Practice over its market research for …
Allergan announces new president
June 26, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, ingram
Allergan has hired Douglas Ingram to be its president and lead the company’s global commercial operations. In this newly established …
Allergan in $958m neurology deal
January 25, 2013Sales and Marketing Allergan, CNS, MAP Pharmaceuticals, migraine
Allergan is to pay $958m for MAP Pharmaceuticals in a deal which sees both companies hoping to reap the benefits …
Botox US bladder indication
January 22, 2013Sales and Marketing Allergan, Botox, FDA, bladder
Allergan’s Botox has been given approval by the FDA for the treatment of overactive bladder (OAB) in adults.Botox (onabotulinumtoxinA) has …
Allergan signs $1.5 billion deal with Molecular Partners
August 22, 2012Research and Development, Sales and Marketing Allergan, Molecular Partners, eye diseases
Allergan has signed a deal potentially worth $1.5 billion with Molecular Partners to develop new drugs for certain eye diseases. …
NICE changes its mind on Botox
May 11, 2012Sales and Marketing Allergan, Botox, NHS, NICE
NICE is now recommending Allergan’s Botox for chronic migraines, reversing its previous decision. The watchdog said in final draft guidance …
NICE frowns on Botox for headache prevention
February 16, 2012Sales and Marketing Allergan, Botox, EMA, NHS, NICE
NICE is not recommending Allergan’s Botox for headache prevention, and has asked the firm for more information on the drug. …
Watchdog frowns on Botox tweet
February 15, 2012Medical Communications Allergan, Chugai, PMCPA, Twitter
Allergan have been found in breach of the UK Code of Practice after an employee used Twitter to communicate about …
Allergan plans $350m expansion of Irish plant
January 10, 2012Manufacturing and Production Allergan, Ireland
Allergan has announced plans to invest $350 million in an expansion of its manufacturing facility in County Mayo, Ireland, a …
FDA approves Botox to treat urinary incontinence
August 25, 2011Sales and Marketing Allergan, Botox, urinary incontinence
Botox has been approved in the US to treat urinary incontinence as manufacturer Allergan continues to expand the brand’s non-cosmetic …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
